Hence, CTX targeting MMP-2 has been widely investigated and proposed as one of the main molecular mechanisms for the development of CTX-based treatments for gliomas [48,49,50,53,112,114,115,116,125,148]. Here, MMP2 is linked to central nervous system cancer.